CA3159744A1 - Calcium-sensing receptor agonist compound and application thereof - Google Patents

Calcium-sensing receptor agonist compound and application thereof Download PDF

Info

Publication number
CA3159744A1
CA3159744A1 CA3159744A CA3159744A CA3159744A1 CA 3159744 A1 CA3159744 A1 CA 3159744A1 CA 3159744 A CA3159744 A CA 3159744A CA 3159744 A CA3159744 A CA 3159744A CA 3159744 A1 CA3159744 A1 CA 3159744A1
Authority
CA
Canada
Prior art keywords
arg
peptide
group
phe
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3159744A
Other languages
English (en)
French (fr)
Inventor
Fangzhou WU
Jin Zhang
Fei Gao
Ran WU
Cheng LIAO
Lei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tuo Jie Biopharmaceutical Co Ltd
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of CA3159744A1 publication Critical patent/CA3159744A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3159744A 2019-12-09 2020-12-08 Calcium-sensing receptor agonist compound and application thereof Pending CA3159744A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911250088.1 2019-12-09
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
CA3159744A1 true CA3159744A1 (en) 2021-06-17

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3159744A Pending CA3159744A1 (en) 2019-12-09 2020-12-08 Calcium-sensing receptor agonist compound and application thereof

Country Status (11)

Country Link
US (1) US20230041996A1 (https=)
EP (1) EP4091623A4 (https=)
JP (1) JP7796013B2 (https=)
KR (1) KR20220110789A (https=)
CN (2) CN114222578B (https=)
AU (1) AU2020399030B2 (https=)
BR (1) BR112022011127A2 (https=)
CA (1) CA3159744A1 (https=)
MX (1) MX2022006892A (https=)
TW (1) TW202122410A (https=)
WO (1) WO2021115272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022257940A1 (zh) * 2021-06-08 2022-12-15 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
EP4353248A4 (en) * 2021-06-08 2024-10-23 Beijing Tuo Jie Biopharmaceutical Co. Ltd. CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407097A (pt) * 2003-04-23 2006-01-24 Japan Tobacco Inc Antagonista do casr
US8999932B2 (en) * 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
EP2643292A1 (en) * 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014508103A (ja) * 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
HRP20161566T1 (hr) * 2011-06-08 2017-02-24 Kai Pharmaceuticals, Inc. Terapijski agensi za reguliranje serumskog fosfora
CN109985228A (zh) * 2011-11-10 2019-07-09 凯伊药品公司 拟钙剂及其使用方法

Also Published As

Publication number Publication date
CN114222578B (zh) 2024-06-25
KR20220110789A (ko) 2022-08-09
AU2020399030B2 (en) 2026-04-09
CN118496313A (zh) 2024-08-16
AU2020399030A1 (en) 2022-06-23
CN114222578A (zh) 2022-03-22
TW202122410A (zh) 2021-06-16
BR112022011127A2 (pt) 2022-08-23
JP2023504904A (ja) 2023-02-07
EP4091623A1 (en) 2022-11-23
WO2021115272A1 (zh) 2021-06-17
EP4091623A4 (en) 2024-01-03
JP7796013B2 (ja) 2026-01-08
MX2022006892A (es) 2022-10-07
US20230041996A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
CA2368431C (en) Melanocortin receptor ligands
AU2002336783B2 (en) Cyclic peptides as G-protein-coupled receptor antagonists
EP3398957B1 (en) Method for synthesizing etelcalcetide
AU2004251616A1 (en) Melanocortin receptor 4(MC4) agonists and their uses
CA2852468A1 (en) Peptidomimetic macrocyles
US20220106367A1 (en) Preparation and use of ginsentides and ginsentide-like peptides
AU2020399030B2 (en) Calcium-sensing receptor agonist compound and application thereof
CA2829020A1 (en) Parathyroid hormone analogs, compositions and uses thereof
EP1997826A2 (en) Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them
RU2827834C1 (ru) Соединение, представляющее собой агонист кальций-чувствительного рецептора, и его применение
WO2022257940A1 (zh) 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用
JP2021080219A (ja) Ｍｍｐ２阻害作用を有する糖鎖付加ポリペプチド
US20240269227A1 (en) Calcium-sensing receptor agonist composition and application thereof
HK40069562B (zh) 钙敏感受体激动剂化合物及其应用
HK40069562A (en) Calcium-sensing receptor agonist compound and application thereof
CN121758557A (zh) 一种补体活性调节剂，其制备方法及医药用途
WO2025242218A1 (zh) 一种多肽激动剂，其制备方法及医药用途
WO2025231285A1 (en) Peptide analogs and methods of using the same
WO2026080980A1 (en) Inhibitors and uses therefor
TW202608907A (zh) 肽類似物及使用其之方法
KR20240117631A (ko) 아펠린성 거대고리 및 이의 용도
JPS6168499A (ja) 新規ペプチド

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241112

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241127

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241127

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251128

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251128

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260312